Immune checkpoint blockade therapy has shown successful clinical outcomes in the treatment of various solid tumors such as head and neck squamous cell carcinoma (HNSCC), melanoma, non- small cell lung cancer (NSCLC) and others. However, immune checkpoint inhibitors work best in patients who exhibit certain tumor biomarkers. In a collaboration with the Department of Hematology Oncology, the Department of Systems Biology, and the Mailman School of Public Health at Columbia University we aim to identify biomarkers which are associated with treatment outcome in patients with solid tumors who underwent immunotherapy. The project includes bioinformatic analysis of sequencing data. Mentoring and training will be provided.

This project is eligible for a matching fund stipend from the Data Science Institute. This is not a guarantee of payment, and the total amount is subject to available funding.

Faculty Advisor

  • Professor: Fatemeh Momen-Heravi
  • Center/Lab: Cancer Biology and Immunology
  • Location: Medical Center
  • We strive to perform innovative science to understand the biological mechanisms underlying carcinogenesis mediated by tumor immune cell interactions, find cancer biomarkers, and exploit tumor vulnerabilities to cure cancer.

Project Timeline

  • Earliest starting date: 9/6/21
  • End date:

Candidate requirements

  • Skill sets: Excel, Basic coding and experience with R software
  • Student eligibility: freshman, sophomore, junior, senior, master’s
  • International students on F1 or J1 visa: eligible
  • Academic Credit Possible: Yes
  • Additional comments: Excellent time management and organizational skills, good writing skils and ability to meet deadlines